

#41 Y.R.
04/13/99
Pre-A
PATENT

DYOU17.001AUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hope, et al.)
)
Appl. No. : Unknown)
)
Filed : Herewith)
)
For : VIRAL THERAPEUTICS)
)
Examiner : Unknown)
)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits, please amend the above-captioned patent application
as follows:

IN THE CLAIMS

3. (Amended) A method according to claim 1 [or 2] further comprising:
- (e) administering a virus to a cell in the absence of [a] said substance which has been determined to disrupt the interaction between the first and second components;
 - (f) administering the virus to the cell in the presence of [the] said substance; and
 - (g) determining if [the] said substance reduces or abolishes the susceptibility of the cell to viral infection or the effects of viral infection.
4. (Amended) A method according to [any one of] claim[s] 1 [to 3] wherein the lipid globule targeting sequence comprises amino acids from 125 to 144 and/or 161 to 166 of the HCV core protein.